Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

12.42
0.0000
Post-market: 12.36-0.0617-0.50%19:40 EDT
Volume:953.58K
Turnover:11.84M
Market Cap:3.96B
PE:33.47
High:12.53
Open:12.46
Low:12.34
Close:12.42
52wk High:15.42
52wk Low:7.02
Shares:319.00M
Float Shares:191.00M
Volume Ratio:0.65
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3711
EPS(LYR):0.2200
ROE:-881.26%
ROA:8.35%
PB:-87.25
PE(LYR):56.45

Loading ...

Amneal Pharmaceuticals' Q1 Adjusted Earnings, Revenue Rise; Agrees to Acquire in Kashiv BioSciences in Cash, Stock Deal

MT Newswires Live
·
Apr 22

Amneal agrees to acquire Kashiv BioSciences, deal seen closing in 2026

Reuters
·
Apr 22

Kashiv Biosciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

THOMSON REUTERS
·
Apr 22

Amneal Pharma: Transaction Is Expected to Close in Second Half of 2026

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals to acquire Kashiv BioSciences

TIPRANKS
·
Apr 22

GUIDANCE: (AMRX) Amneal Pharmaceuticals Expects 2026 Revenue Range $3.05B - $3.15B, vs. FactSet Est of $3.1B

MT Newswires Live
·
Apr 22

BRIEF-Amneal Pharmaceuticals Outlook FY Revenue USD 3,050-3,150 Million Vs. IBES Estimate USD 3,097 Million

Reuters
·
Apr 22

Amneal Pharma - Deal Expected to Deliver $400 Mln-$500 Mln in Financial Benefits

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Adjusted Ebitda USD 740-770 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharma - Expects Over 12 Commercial Biosimilars and 20 Pipeline Products by 2030

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Inc FY2026 Shr View $0.99, REV View $3.10 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Operating Cash Flow USD 350-400 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Revenue USD 3,050-3,150 Million VS. Ibes Estimate USD 3,097 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Capex USD 110 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharma: Deal Expected to Provide Substantial Financial Synergies Through Elimination of Upcoming Milestone & Royalty Obligations Through 2030

THOMSON REUTERS
·
Apr 22

Amneal Pharma - Q1 2026 Preliminary Consolidated Net Revenue $723 Mln, up 4% Year Over Year

THOMSON REUTERS
·
Apr 22

Amneal Pharma - Raises 2026 Adj Diluted EPS Guidance to $0.95-$1.05

THOMSON REUTERS
·
Apr 22

Amneal Agrees to Acquire Kashiv Biosciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

THOMSON REUTERS
·
Apr 22

Amneal says Phase 4 ELEVATE-PD interim data show CREXONT adds 3 hours “Good On” time

Reuters
·
Apr 20

Amneal Pharma - Interim Phase 4 Elevate-Pd Data Shows Clinically Meaningful Benefits of Crexont

THOMSON REUTERS
·
Apr 20